Efficacy and safety of sultamicillin (750 mg bid) compared with amoxycillin/clavulanate (625 mg tid) in patients with umcomplicated urinary tract infections.
In an open, randomized, multicentre study, two aminopenicillin/beta-lactamase inhibitor combinations for oral administration were compared in 132 out-patients with umcomplicated urinary tract infections. Two groups of 66 patients each received a dose of 750 mg sultamicillin (STM) bid or 625 mg amoxycillin/clavulanic (AMX/CLA) acid tid. The evaluation of efficacy was performed on a total of 126 patients (STM: 64, AMX/CLA: 62) in whom bacteria were isolated before the start of treatment. In the STM group, 61 patients (95.3%) were treated successfully (cure and elimination of the organism), versus 56 patients in the AMX/CLA group (90.3%). Both combinations were well tolerated; troublesome adverse effects were not seen. Sultamicillin is an efficacious treatment for acute urinary tract infections, like AMX/CLA. Moreover, whereas STM is as efficacious as AMX/CLA, and is as well tolerated, it has the advantage of requiring only twice-daily dosing.